Tradestie Institutional Equity Comparison Engine

ABOS vs FBL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABOS Overall Edge

ABOS Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acumen Pharmaceuticals, Inc. Common Stock (ABOS) driven by superior Growth & Margin, Options & Structure while FBL counters with relative strength in Momentum & Technical. Fundamentally, ABOS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FBL at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABOS sits in UNCLASSIFIED (41st %ile IV; Dealer Gamma Walls on Pro) against FBL sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABOS N/M vs FBL N/M Fwd P/E
Growth & Margin Winner ABOS
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner FBL
1Y -88.7% vs -20.8% ยท 52W Pos 0% vs 24%
Options & Structure Winner ABOS
UNCLASSIFIED (41st %ile IV) vs UNCLASSIFIED (36th %ile IV)
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.21
-4.04% 1D
Market Cap $15.8M
1M Return -87.85%
1Y Return -88.65%
Forward P/E N/M
Unified AI Score
57.4 / 100 HOLD
Tech 76.0 Fund 62.0 Flow 68.0 Mom 55.0
FBL NASDAQ
GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF
Institutional Equity
$22.88
-5.22% 1D
Market Cap N/A
1M Return -23.99%
1Y Return -20.78%
Forward P/E N/M
Unified AI Score
56.6 / 100 HOLD
Tech 65.0 Fund 58.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABOS -88.65% FBL -20.78% Spread: +67.87 pp (FBL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABOS TTM Op. Margin: 0.0% FBL TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs FBL. Trailing 12-month operating profitability (ABOS 0.0% vs FBL N/A) and valuation multiples (ABOS N/M vs FBL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABOS (6) vs FBL (2)
Institutional Metric ABOS FBL Criterion Row Winner
Market Capitalization Scale $15.8M N/A Larger Scale ABOS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth ABOS
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin ABOS
Net Profit Margin Profitability 0.0% N/A Higher Margin ABOS
Return on Equity (ROE) Capital Efficiency -162.7% N/A Higher ROE ABOS
52-Week Range Position Momentum 0% ($0โ€“$4) 24% ($17โ€“$40) Stronger Trend FBL
Beta / 30D Volatility Risk Regime 2.67ฮฒ ยท 335% Vol 2.86ฮฒ ยท 82% Vol Lower Realized Risk FBL
Unified Institutional Score Composite Signal 57.4 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ABOS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABOS vs FBL Buy Guide
ABOS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 41st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FBL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live FBL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABOS nor FBL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.